Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway

HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16 cervical cancer progression and the underlying mechanism. The transcript and protei...

Full description

Saved in:
Bibliographic Details
Published inMolecular medicine (Cambridge, Mass.) Vol. 27; no. 1; pp. 130 - 12
Main Authors Zeng, Jie, He, Si-Li, Li, Li-Jie, Wang, Chen
Format Journal Article
LanguageEnglish
Published England BioMed Central 19.10.2021
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16 cervical cancer progression and the underlying mechanism. The transcript and protein expression of Hsp90 in normal cervical and HPV16 cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16 cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated. Hsp90 expression was up-regulated in HPV16 cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown. In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16 cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16 cervical cancers.
AbstractList Abstract Background HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16+ cervical cancer progression and the underlying mechanism. Methods The transcript and protein expression of Hsp90 in normal cervical and HPV16+ cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16+ cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated. Results Hsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown. Conclusion In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16+ cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16+ cervical cancers.
HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16+ cervical cancer progression and the underlying mechanism.BACKGROUNDHPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16+ cervical cancer progression and the underlying mechanism.The transcript and protein expression of Hsp90 in normal cervical and HPV16+ cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16+ cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated.METHODSThe transcript and protein expression of Hsp90 in normal cervical and HPV16+ cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16+ cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated.Hsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown.RESULTSHsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown.In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16+ cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16+ cervical cancers.CONCLUSIONIn this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16+ cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16+ cervical cancers.
HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16 cervical cancer progression and the underlying mechanism. The transcript and protein expression of Hsp90 in normal cervical and HPV16 cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16 cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated. Hsp90 expression was up-regulated in HPV16 cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown. In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16 cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16 cervical cancers.
ArticleNumber 130
Author Li, Li-Jie
Wang, Chen
Zeng, Jie
He, Si-Li
Author_xml – sequence: 1
  givenname: Jie
  surname: Zeng
  fullname: Zeng, Jie
– sequence: 2
  givenname: Si-Li
  surname: He
  fullname: He, Si-Li
– sequence: 3
  givenname: Li-Jie
  surname: Li
  fullname: Li, Li-Jie
– sequence: 4
  givenname: Chen
  orcidid: 0000-0003-1780-3216
  surname: Wang
  fullname: Wang, Chen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34666670$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhS1URB_wB1ggL9mY-Dnj2SBVbSFRIxGhwoKNdcfjSV1NxoPtBPXf4zQtoiywZPnKPvc7ku85RUdjGB1Cbxn9wJiuZolRyimhnBFKhZaEv0AnTHFNRKX0UalpXRGmFDtGpyndFTVTUr1Cx0JWZdX0BP2Yp6mheDuR6NbbAbJLeHVJlgzngKcYNiE7PF99J1NIPvudw9bFnbcwYAtjqfHOA55ffeWz1UJcz86vb_AE-fYX3L9GL3sYknvzeJ6hb5-ubi7mZPnl8-LifEmsqppMhJQdWKsk64DpHpyCrlUSnGi5Ftz1rhbK1rrRQrW0qSrgtWM9t30DjbZWnKHFgdsFuDNT9BuI9yaANw8XIa4NxOzt4IzqJJV9r5WTnWzbTpdva3rKW1F1XHFVWB8PrGnbblxn3ZgjDM-gz19Gf2vWYWe04rLsAnj_CIjh59albDY-WTcMMLqwTYYrLSlTVb2Xvvvb64_J03CKQB8ENoaUouuN9RmyD3trPxhGzT4H5pADU6ZrHnJg9mz-T-sT_T9NvwFndLOf
CitedBy_id crossref_primary_10_1002_cam4_4828
crossref_primary_10_1007_s11596_024_2898_7
crossref_primary_10_1016_j_fitote_2024_106194
crossref_primary_10_1016_j_heliyon_2023_e16683
crossref_primary_10_1631_jzus_B2300457
crossref_primary_10_3390_ijms25136835
crossref_primary_10_3389_fphar_2022_806284
crossref_primary_10_1016_j_cellsig_2023_110639
crossref_primary_10_1080_02656736_2023_2259140
crossref_primary_10_3389_fonc_2023_1111778
crossref_primary_10_1016_j_intimp_2023_111077
crossref_primary_10_3389_fonc_2024_1488730
crossref_primary_10_1016_j_intimp_2024_113186
crossref_primary_10_1166_sam_2024_4597
crossref_primary_10_1007_s12013_024_01502_7
crossref_primary_10_3389_fphar_2023_1218467
crossref_primary_10_3892_mmr_2023_12933
crossref_primary_10_1016_j_ejmech_2024_116572
crossref_primary_10_3390_ijms23169317
crossref_primary_10_1016_j_abb_2022_109449
crossref_primary_10_1038_s41417_023_00682_3
crossref_primary_10_1186_s40779_024_00586_9
Cites_doi 10.3390/cells9030632
10.1002/jcp.29590
10.1186/s13148-015-0084-2
10.1016/j.ejmech.2019.111725
10.1002/ijc.31357
10.1158/1541-7786.MCR-10-0534
10.1007/s00044-020-02534-3
10.1038/s41388-018-0252-x
10.1016/j.cell.2017.08.001
10.1128/mBio.02068-14
10.1158/0008-5472.CAN-14-3362
10.1007/978-1-4939-7477-1_28
10.1007/s13105-020-00730-8
10.1016/S0140-6736(16)32417-5
10.2174/1566524015666150114111745
10.1007/s00280-007-0522-8
10.1007/s00262-017-2017-8
10.1038/nature19328
10.1002/ijc.27739
10.1158/1940-6207.PREV-09-A74
10.1016/j.ejphar.2020.173355
10.1186/1471-2407-4-59
10.1038/sj.bjc.6601024
10.1158/1078-0432.CCR-13-2797
10.1038/nchembio.1335
10.1016/S2214-109X(19)30482-6
10.1084/jem.20160801
10.1016/j.bcp.2019.04.010
10.3389/fphar.2020.537265
10.1007/s12032-019-1299-4
10.1038/s41598-019-52652-1
10.1042/CBI20110473
10.21037/tlcr.2019.08.22
10.1155/2019/9675450
10.1186/s13058-020-01271-0
ContentType Journal Article
Copyright 2021. The Author(s).
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s10020-021-00384-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1528-3658
EndPage 12
ExternalDocumentID oai_doaj_org_article_5d404ff85e4d4bbd80389f02b36d2525
PMC8524852
34666670
10_1186_s10020_021_00384_2
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: 2020JJ5868
GroupedDBID ---
-ET
0R~
123
29M
2WC
36B
5RE
5VS
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFO
ACMJI
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IH2
IHR
ISR
ITC
KQ8
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
RBZ
RNS
ROL
RPM
RSV
SDH
SJN
SOJ
SV3
TR2
UKHRP
WOQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c569t-344dacc541da18fae5adb54ae3b2832efe735c789835b0966a27e1f2cf9a98cc3
IEDL.DBID DOA
ISSN 1076-1551
1528-3658
IngestDate Wed Aug 27 01:07:53 EDT 2025
Thu Aug 21 18:45:57 EDT 2025
Fri Jul 11 00:12:11 EDT 2025
Thu Apr 03 07:00:34 EDT 2025
Thu Apr 24 22:55:47 EDT 2025
Tue Jul 01 01:25:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hsp90
PD-L1
HER2
Cervical cancer
HPV16
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c569t-344dacc541da18fae5adb54ae3b2832efe735c789835b0966a27e1f2cf9a98cc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-1780-3216
OpenAccessLink https://doaj.org/article/5d404ff85e4d4bbd80389f02b36d2525
PMID 34666670
PQID 2584015672
PQPubID 23479
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_5d404ff85e4d4bbd80389f02b36d2525
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8524852
proquest_miscellaneous_2584015672
pubmed_primary_34666670
crossref_citationtrail_10_1186_s10020_021_00384_2
crossref_primary_10_1186_s10020_021_00384_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211019
PublicationDateYYYYMMDD 2021-10-19
PublicationDate_xml – month: 10
  year: 2021
  text: 20211019
  day: 19
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular medicine (Cambridge, Mass.)
PublicationTitleAlternate Mol Med
PublicationYear 2021
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References K Kryeziu (384_CR20) 2019; 1871
VR Juneja (384_CR19) 2017; 214
Q Liu (384_CR25) 2020; 76
S Wang (384_CR34) 2018; 37
J-q Yuan (384_CR37) 2020
J Schwock (384_CR31) 2008; 61
S Daunys (384_CR10) 2019; 9
M Arbyn (384_CR3) 2020; 8
G Clifford (384_CR7) 2003; 89
XD Pei (384_CR30) 2020; 883
MB Cox (384_CR9) 2018
Z Hao (384_CR15) 2010; 37
A Chavez-Blanco (384_CR6) 2004; 4
L Hu (384_CR16) 2019
PB Calderon (384_CR5) 2019; 164
L-S Fu (384_CR11) 2020; 29
D Li (384_CR22) 2011; 9
M Atefi (384_CR4) 2014; 20
Y Wen (384_CR35) 2000; 60
G Gao (384_CR12) 2013; 132
NV Jordan (384_CR18) 2016; 537
D Xu (384_CR36) 2020; 9
W Huang (384_CR17) 2020; 235
Y-L Liou (384_CR24) 2015; 7
S-S Li (384_CR23) 2011; 26
M-X Zou (384_CR39) 2016; 8
Y Gao (384_CR13) 2018; 143
A Giatromanolaki (384_CR14) 2019; 36
L Zeng (384_CR38) 2015; 15
KJ Lastwika (384_CR21) 2016; 76
S Loibl (384_CR26) 2017; 389
W Wang (384_CR33) 2017; 66
J Codony-Servat (384_CR8) 2019; 8
S Mehndiratta (384_CR27) 2020; 185
M Ajiro (384_CR1) 2015
L Am (384_CR2) 2012; 36
L Mirabello (384_CR28) 2017; 170
PD Patel (384_CR29) 2013; 9
C Vernieri (384_CR32) 2020; 22
References_xml – volume: 9
  start-page: 632
  year: 2020
  ident: 384_CR36
  publication-title: Cells
  doi: 10.3390/cells9030632
– volume: 235
  start-page: 6942
  year: 2020
  ident: 384_CR17
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.29590
– volume: 7
  start-page: 50
  year: 2015
  ident: 384_CR24
  publication-title: Clin Epigenet
  doi: 10.1186/s13148-015-0084-2
– volume: 185
  start-page: 111725
  year: 2020
  ident: 384_CR27
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2019.111725
– volume: 8
  start-page: 3274
  year: 2016
  ident: 384_CR39
  publication-title: Am J Transl Res
– volume: 143
  start-page: 931
  year: 2018
  ident: 384_CR13
  publication-title: Int J Cancer
  doi: 10.1002/ijc.31357
– volume: 9
  start-page: 577
  year: 2011
  ident: 384_CR22
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-10-0534
– volume: 29
  start-page: 942
  year: 2020
  ident: 384_CR11
  publication-title: Med Chem Res
  doi: 10.1007/s00044-020-02534-3
– volume: 37
  start-page: 4164
  issue: 30
  year: 2018
  ident: 384_CR34
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0252-x
– volume: 170
  start-page: 1164
  year: 2017
  ident: 384_CR28
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.001
– year: 2015
  ident: 384_CR1
  publication-title: MBio
  doi: 10.1128/mBio.02068-14
– volume: 76
  start-page: 227
  year: 2016
  ident: 384_CR21
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-3362
– start-page: 397
  volume-title: Chaperones
  year: 2018
  ident: 384_CR9
  doi: 10.1007/978-1-4939-7477-1_28
– volume: 76
  start-page: 279
  year: 2020
  ident: 384_CR25
  publication-title: J Physiol Biochem
  doi: 10.1007/s13105-020-00730-8
– volume: 389
  start-page: 2415
  year: 2017
  ident: 384_CR26
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32417-5
– volume: 1871
  start-page: 240
  year: 2019
  ident: 384_CR20
  publication-title: Biochim Biophys Acta (BBA)
– volume: 15
  start-page: 38
  year: 2015
  ident: 384_CR38
  publication-title: Curr Mol Med
  doi: 10.2174/1566524015666150114111745
– volume: 61
  start-page: 669
  year: 2008
  ident: 384_CR31
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-007-0522-8
– volume: 66
  start-page: 1379
  year: 2017
  ident: 384_CR33
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-017-2017-8
– volume: 537
  start-page: 102
  year: 2016
  ident: 384_CR18
  publication-title: Nature
  doi: 10.1038/nature19328
– volume: 60
  start-page: 6841
  year: 2000
  ident: 384_CR35
  publication-title: Cancer Res
– volume: 132
  start-page: 882
  year: 2013
  ident: 384_CR12
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27739
– volume: 37
  start-page: 74
  year: 2010
  ident: 384_CR15
  publication-title: Cancer Res Prev Treat
  doi: 10.1158/1940-6207.PREV-09-A74
– volume: 883
  start-page: 173355
  year: 2020
  ident: 384_CR30
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2020.173355
– volume: 4
  start-page: 1
  year: 2004
  ident: 384_CR6
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-4-59
– volume: 89
  start-page: 101
  year: 2003
  ident: 384_CR7
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601024
– volume: 20
  start-page: 3446
  year: 2014
  ident: 384_CR4
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-2797
– volume: 9
  start-page: 677
  year: 2013
  ident: 384_CR29
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.1335
– volume: 8
  start-page: e191
  year: 2020
  ident: 384_CR3
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(19)30482-6
– volume: 214
  start-page: 895
  year: 2017
  ident: 384_CR19
  publication-title: J Exp Med
  doi: 10.1084/jem.20160801
– volume: 26
  start-page: 1573
  year: 2011
  ident: 384_CR23
  publication-title: Oncol Rep
– volume: 164
  start-page: 177
  year: 2019
  ident: 384_CR5
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2019.04.010
– year: 2020
  ident: 384_CR37
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2020.537265
– volume: 36
  start-page: 76
  year: 2019
  ident: 384_CR14
  publication-title: Med Oncol
  doi: 10.1007/s12032-019-1299-4
– volume: 9
  start-page: 1
  year: 2019
  ident: 384_CR10
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-52652-1
– volume: 36
  start-page: 893
  year: 2012
  ident: 384_CR2
  publication-title: Cell Biol Int
  doi: 10.1042/CBI20110473
– volume: 8
  start-page: 340
  year: 2019
  ident: 384_CR8
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr.2019.08.22
– year: 2019
  ident: 384_CR16
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2019/9675450
– volume: 22
  start-page: 1
  year: 2020
  ident: 384_CR32
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-020-01271-0
SSID ssj0021545
Score 2.4662776
Snippet HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic...
Abstract Background HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 130
SubjectTerms Animals
B7-H1 Antigen - genetics
B7-H1 Antigen - metabolism
Cell Line, Tumor
Cervical cancer
Female
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques - methods
HER2
HPV16
Hsp90
HSP90 Heat-Shock Proteins - genetics
HSP90 Heat-Shock Proteins - metabolism
Human papillomavirus 16 - physiology
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Papillomavirus Infections - genetics
Papillomavirus Infections - metabolism
Papillomavirus Infections - virology
PD-L1
Phosphatidylinositol 3-Kinases - metabolism
Proto-Oncogene Proteins c-akt - metabolism
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - metabolism
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction - genetics
Transferases - genetics
Transferases - metabolism
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - metabolism
Uterine Cervical Neoplasms - virology
Xenograft Model Antitumor Assays - methods
Title Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway
URI https://www.ncbi.nlm.nih.gov/pubmed/34666670
https://www.proquest.com/docview/2584015672
https://pubmed.ncbi.nlm.nih.gov/PMC8524852
https://doaj.org/article/5d404ff85e4d4bbd80389f02b36d2525
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9swEBbtlkIvpe-m3QYVeisith6WfGy2WdzXEkK3hL0IPelCcUIeW_bfV2M5YVNKe-nFB1u2xMzI8w2a-QahNyyGBBIoI1RFRzh1lNTSO1I5JaWIjHkBBc5fzqrmnH-ci_mNVl-QE5bpgbPgRsLzgseoROCeW-sVMMLFglpWeSpox16afN4umOpDLQAGOduwIgAKduUyqoKiOQiZIDUBjsU4oQcuqWPu_xPc_D1r8oYbOn2A7vf4Eb_L636IboX2EbqbO0peP0YXzXpZF3i7JKvcZD6s8fQ9-VzizQIvu9S7gJvpN5KTta4Cdt3PIn3Sgf5X-OrS4GYyo6PpB_ZplCAghqbFP831E3R-Ovl60pC-fQJxoqo3hHHujXOCl96UKpogjLeCm8As9CcKMUgmnFR1AmE2RTKVoTKUkbpYm1o5x56io3bRhucIC5u2bkJ-jsrIk8szzkYVrOXRGxEKP0DlToLa9dzi0OLih-5iDFXpLHWdpK47qWs6QG_37ywzs8ZfR49BMfuRwIrd3Ui2ontb0f-ylQF6vVOrTrsIjkZMGxbbtaYJh0FRuUwTPctq3k_FeArxKlkMkDwwgIO1HD5pL793TN1KAGMcffE_Fv8S3aNgtJBNUx-jo81qG14lQLSxQ3RbzuUQ3RlPzqazYbcT0nU2vvgFOjIG8g
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hsp90+up-regulates+PD-L1+to+promote+HPV-positive+cervical+cancer+via+HER2%2FPI3K%2FAKT+pathway&rft.jtitle=Molecular+medicine+%28Cambridge%2C+Mass.%29&rft.au=Zeng%2C+Jie&rft.au=He%2C+Si-Li&rft.au=Li%2C+Li-Jie&rft.au=Wang%2C+Chen&rft.date=2021-10-19&rft.issn=1528-3658&rft.eissn=1528-3658&rft.volume=27&rft.issue=1&rft.spage=130&rft_id=info:doi/10.1186%2Fs10020-021-00384-2&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-1551&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-1551&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-1551&client=summon